FDA approves oxycodone hydrochloride and naltrexone hydrochloride ER capsules CII with…

FDA has approved oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER—Pfizer) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, long-term opioid treatment. The drug is the only oxycodone with oral abuse-deterrent features described in the labeling.

FDA has approved oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER—Pfizer) extended-release capsules, for oral use, CII for the (more…)

FDA Approves Abuse-Deterrent, Extended-Release Oxycodone/Naltrexone (Troxyca ER) for Pain…

The FDA has given the nod to Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride, Pfizer) extended-release capsules for oral use (CII) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Troxyca ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal (more…)

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for … -…

| Source: Elite Pharmaceuticals, Inc.

NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite’s twice daily abuse-deterrent oxycodone product which utilizes Elite’s proprietary pharmacological abuse-deterrent technology.

The study, initiated in July of 2014, demonstrated Elite’s product is bioequivalent (more…)